Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET (NCT06784752)
A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients Newly Diagnosed With Grade 1 and Grade 2 (Ki-67 <10%) Advanced GEP-NET With High Disease Burden (NETTER-3)
🩺 Plain-English Summary (8th-Grade Level)
The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+), well differentiated Grade1 and Grade 2 (G1 and G2) (Ki-67 \<10%) advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with high disease burden
Who can join: Review the eligibility criteria below.
Location: Mayo Clinic Arizona — Scottsdale, Arizona
Age range: 12 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (65 Sites)
Showing the first 25 of 65 sites.
- Mayo Clinic Arizona — Scottsdale, Arizona
- Highlands Oncology Group — Fayetteville, Arkansas
- Rocky Mountain Cancer Centers — Denver, Colorado
- Hartford Hospital — Hartford, Connecticut
- Yale New Haven Hospital — New Haven, Connecticut
- Mayo Clinic Jacksonville — Jacksonville, Florida
- Winship Cancer Institute — Atlanta, Georgia
- St Elizabeth Healthcare — Edgewood, Kentucky
- LSU Medical Center — New Orleans, Louisiana
- Henry Ford Hospital — Detroit, Michigan
- Mount Sinai Medical Center — New York, New York
- Piedmont Healthcare — Winston-Salem, North Carolina
- Tennessee Oncology — Nashville, Tennessee
- TxO Austin Midtown — Austin, Texas
- Texas Oncology — Dallas, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- Virginia Oncology Associates — Norfolk, Virginia
- Blue Ridge Cancer Center — Wytheville, Virginia
- Northwest Medical Specialties — Tacoma, Washington
- Novartis Investigative Site — Edmonton, Alberta
- Novartis Investigative Site — London, Ontario
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Beijing,
- Novartis Investigative Site — Beijing,
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
Explore by condition: All Somatostatin Receptor Positive (SSTR+) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.